ACS Medicinal Chemistry Letters · 2016 · 51 citations · 12 references
MedicineMedicinal ChemistryPharmacologyAntimicrobial PharmacologyDrug DesignDrug DiscoveryAntibacterial AgentsAntibacterial PharmacologyDrug-susceptible Tuberculosis TreatmentEnzyme InhibitionIn Vitro PharmacologyLead Compound DesignDrug-resistant PathogensMinimum Inhibitory Concentration DeterminationMycobacterium Tuberculosis InfectionMycobacterium Tuberculosis PathogenesisTuberculosis Drug DevelopmentTuberculosis Drug Resistance
2-(Quinolin-4-yloxy)acetamides have been described as potent in vitro inhibitors of Mycobacterium tuberculosis growth. Herein, additional chemical modifications of lead compounds were carried out, yielding highly potent antitubercular agents with minimum inhibitory concentration (MIC) values as low as 0.05 μM. Further, the synthesized compounds were active against drug-resistant strains and were devoid of apparent toxicity to Vero and HaCat cells (IC50s ≥ 20 μM). In addition, the 2-(quinolin-4-yloxy)acetamides showed intracellular activity against the bacilli in infected macrophages with action similar to rifampin, low risk of drug-drug interactions, and no sign of cardiac toxicity in zebrafish (Danio rerio) at 1 and 5 μM. Therefore, these data indicate that this class of compounds may furnish candidates for future development to, hopefully, provide drug alternatives for tuberculosis treatment.
12
Juan-Carlos Palomino, Anandi Martin, Mirtha Camacho et al. · Antimicrobial Agents and Chemotherapy · 2002 · 1.2K citations · Full text
Fueling Open‐Source Drug Discovery: 177 Small‐Molecule Leads against Tuberculosis
Lluís Ballell, Robert H. Bates, Rob J. Young et al. · ChemMedChem · 2013 · 310 citations · Full text
Annamaria Lilienkampf, Jialin Mao, Baojie Wan et al. · Journal of Medicinal Chemistry · 2009 · 306 citations